Value through Innovation27 July 2016

Clinical Study Results

  • BI 11054 - Healthy
    Clinical Study Number 1250.1
    Study Indication Healthy
    Product BI 11054
    Generic Name BI 11054
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, double-blind, placebo-controlled (within dose groups) study to assess safety, tolerability, and pharmacokinetics of single rising inhaled doses (0.5 µg to 70 µg administered with Respimat®) of BI 11054 CL in healthy male volunteers

    Study Document Trial synopsis 1250.1 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.